H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on MediWound (MDWD) to $25 from $28 and keeps a Buy rating on the shares following the Q3 report. The firm says NexoBrid supply may soon meet demand.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter